International Stem Cell Corporation (OTCBB: ISCO),
www.internationalstemcell.com,
announced today that it has expanded its market awareness program by
joining www.StockProfile.com,
a customized web-based platform showcasing emerging growth stocks.
StockProfile.com provides the investing public with a free unique
information portal for investors who like to conduct their own research
and make their own investment decisions. The platform allows users to
review and investigate dynamic publicly traded companies in a
user-friendly environment.
International Stem Cell Corporation is pleased to provide corporate
information to StockProfile.com's independent investors seeking
information about new growth companies. The profile is listed at www.StockProfile.com
and can be viewed by searching under the stock symbol ISCO.
Brian Lundstrom, President of ISCO said, "This is another important step
ISCO is taking to ensure that its shareholders and the investment
community have continued access to information about our latest
announcements, products and services. We're pleased to add
StockProfile.com to our market awareness program and we will continue to
explore additional market outreach strategies."
ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):
International Stem Cell Corporation is a California-based biotechnology
company focused on therapeutic and research products. ISCO's core
technology, parthenogenesis, results in creation of pluripotent
human stem cells from unfertilized oocytes (eggs). ISCO scientists have
created the first parthenogenic, homozygous stem cell line that
can be a source of therapeutic cells with minimal immune rejection after
transplantation into hundreds of millions of individuals of differing
sexes, ages and racial groups. This offers the potential to create the
first true stem cell bank, UniStemCell™, while avoiding the ethical
issue of using fertilized eggs. ISCO also produces and markets
specialized cells and growth media for therapeutic research worldwide
through its subsidiary Lifeline Cell Technology. More information is
available at ISCO's website, www.internationalstemcell.com
To subscribe to receive ongoing corporate communications please click on
the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
FORWARD-LOOKING STATEMENTS: Statements pertaining to anticipated future financial and/or
operating results, future growth in research, technology, clinical
development and potential joint venture and other opportunities for the
company and its subsidiary, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements that
are not historical fact (including, but not limited to statements that
contain words such as "will," "believes," "plans," "anticipates,"
"expects," "estimates,") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties,
including, without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, application of capital resources among competing uses,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities
and Exchange Commission filings. The company disclaims any intent or
obligation to update these forward-looking statements.
Key Words: Stem Cells, Biotechnology, Parthenogenesis
International Stem Cell Corporation Kenneth C. Aldrich, Chairman 760-940-6383 kaldrich@intlstemcell.com Or Brian
Lundstrom, President 760-640-6383 bl@intlstemcell.com |